Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Interest Expense
Cost of servicing the company's debt during the period.
Bausch Health Companies Inc.NYSE: BHC
Interest Expense · Q2 FY2026 · quarter ended Jun 2026
Interest expense dips below year-ago levels
Q2 FY2026 interest expense of $396M fell 14.8% year over year, behind the +8.7% change in trailing-twelve-month interest expense. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Interest expense amounted to 15.6% of revenue in FY2025, up 1.2 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -14.8% toward the trailing-twelve-month pace of +8.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 1.6B USD
- Year-over-year change
- +15.6%
- 4-year CAGR
- +3.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.6B | +15.6% |
| FY2024 | 2024-12-31 | 1.39B | +4.5% |
| FY2023 | 2023-12-31 | 1.33B | -9.3% |
| FY2022 | 2022-12-31 | 1.46B | +2.7% |
| FY2021 | 2021-12-31 | 1.43B | — |
Interest Expense vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 interest expense of $1.61B is the highest of the 11 companies compared; the peer median is $31.31M.
- Its year-over-year change of +8.7% is the 5th highest of 7, against a peer median of +40.1%.
- Interest expense amounts to 14.8% of revenue for BHC, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.61B | +8.7% | +3.1% | 14.8% | |
| LTM Jun 2026 | $163.1M | -9.0% | +1.4% | 3.9% | |
| LTM Mar 2026 | $154.46M | +1601.6% | +17.7% | 27.6% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $103.76M | -0.5% | +51.2% | 4.4% |
| LTM Mar 2026 | $90M | +28.6% | +10.6% | 2.4% | |
| LTM Mar 2026 | $32.02M | +51.7% | -10.6% | 3.5% | |
| LTM Jun 2026 | $30.59M | +51.6% | +25.2% | 2.3% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2025 | $0 | — | +63.9% | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding BHC) | $31.31M | +40.1% | +17.7% | 2.4% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.43B | 8.12B | 8.76B | 9.63B | 10.27B |
| Cost of Revenue | 2.39B | 2.36B | 2.56B | 2.78B | 3.01B |
| Gross Profit | 6.04B | 5.76B | 6.2B | 6.84B | 7.25B |
| Gross Margin | 71.6% | 70.9% | 70.8% | 71.1% | 70.7% |
| Research & Development | 473M | 530M | 604M | 634M | 629M |
| Selling, General & Admin | 2.49B | 2.53B | 2.9B | 3.28B | 3.44B |
| Operating Expenses | 5.59B | 5.31B | 5.24B | 5.3B | 5.07B |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| EBITDA | 3.26B | 2.88B | 2.89B | 3.13B | 3.18B |
| EBITDA Margin | 38.7% | 35.4% | 32.9% | 32.6% | 31.0% |
| Operating Income | 450M | 454M | 963M | 1.55B | 2.19B |
| Operating Margin | 5.3% | 5.6% | 11.0% | 16.1% | 21.3% |
| Interest Income | 7M | 14M | 26M | 33M | 48M |
| Interest Expense | 1.43B | 1.46B | 1.33B | 1.39B | 1.6B |
| Other Income / Expenses | (1.47B) | (583M) | (1.35B) | (1.38B) | (1.82B) |
| Income Before Tax | (1.02B) | (129M) | (390M) | 167M | 367M |
| Pre-Tax Margin | -12.1% | -1.6% | -4.5% | 1.7% | 3.6% |
| Income Tax Expense | (87M) | 83M | 221M | 239M | 247M |
| Net Income | (948M) | (225M) | (592M) | (46M) | 157M |
| Net Margin | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
| EPS (Basic) | (2.61) | (0.62) | (1.62) | (0.13) | 0.43 |
| EPS (Diluted) | (2.61) | (0.62) | (1.62) | (0.13) | 0.43 |
| Weighted Avg Shares | 358.9M | 362M | 364.9M | 368M | 370.9M |
| Weighted Avg Shares (Diluted) | 358.9M | 362M | 364.9M | 368M | 375M |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.